QLF32004 Injection for the Treatment of Patients With Advanced Malignant Tumors
To determine the safety, tolerability, and recommended dose (RP2D) of QLF32004 in patients with advanced malignancies.
Advanced Tumor
DRUG: QLF32004
Dose-Limiting Toxicity (DLT), 21 days|Maximum Tolerated Dose (MTD), 21 days|Recommended Phase 2 Dose (RP2D), 12 month
Treatment-Emergent Adverse Event (TEAE), 21 days|Maximum Observed Plasma Concentration (Cmax), 21 days|Serious Adverse Event (SAE), 12 month|Area Under The Curve (AUC), 21 days
To determine the safety, tolerability, and recommended dose (RP2D) of QLF32004 in patients with advanced malignancies.